![Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [young asian father with two small children]](https://cdn.prod.website-files.com/60a04ec06ae74b7d42714803/60a052786ae74bed2c715b6a_header-image.jpg)
![Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [logo]](https://cdn.prod.website-files.com/60a04ec06ae74b7d42714803/614e1d7e6ee87061cd381518_adela-logo-rgb.png){kind=logo}
Adela’s tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & neck cancer, regardless of HPV status. The test identified recurrences in head & neck cancer up to 14.9 months before standard of care clinical exam and imaging.
Study outcomes demonstrate potential for Adela’s MRD test to inform adjuvant treatment decisions and predict and monitor for recurrence in patients with head & neck cancer, regardless of HPV status
Results from this training dataset demonstrate potential for Adela’s MRD test to inform adjuvant treatment decisions and monitor for recurrence in patients with HPV-positive and HPV-negative head & neck cancer
Data will demonstrate ability of the assay to predict recurrence in patients treated for head & neck cancer
Ms. Alderson is a seasoned healthcare CEO who brings over 20 years of experience building early-stage companies at the intersection of technology and healthcare
Individuals with higher quantities of cancer signal from cell-free DNA (cfDNA) prior to treatment had a significantly increased likelihood of recurrence post-treatmentAdela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis
Individuals with higher quantities of circulating tumor DNA (ctDNA) prior to treatment had a significantly increased likelihood of recurrence or progression. Adela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis.
Investors include F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, Labcorp and RA Capital Management. Proceeds from this financing will be used to advance Adela’s technology platform and commercialize Adela’s first product for MRD monitoring, while further developing a multi-cancer early detection (MCED) product. Lisa Alderson – seasoned CEO and healthcare innovator - appointed as Interim CEO of Adela.
A life sciences veteran who has led organizations through the successful development, launch and scale-up of multiple, first-in class products.
Adela’s platform demonstrated strong detection for early stage cancers
Adela, Inc. announced today that it will present data demonstrating the ability of its genome-wide methylome enrichment platform to detect multiple types of cancer at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.
Daniel De Carvalho, PhD will deliver a plenary session titled “Cancer Early Detection, Classification and Monitoring using Plasma Cell-Free DNA Methylomes” at the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer on November 18, 2022.
Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the first participant in a multi-center study supporting the development and validation of its genome-wide methylome enrichment platform for the early detection of cancer.
Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.
Adela’s technology detects signals of early disease with high sensitivity through efficient mining of the entire methylome
